Value through Innovation16 January 2013
Our Research & Development Drive
Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
Boehringer Ingelheim's Research & Development facts:
- Our research & development comprises four major research & development sites and three smaller specialized sites worldwide.
- During the past decade Boehringer Ingelheim conducted or sponsored 1,320 studies with approximately one million patients on 106 substances in 87 countries.
- We have more than 7,000 highly qualified people working in research & development out of more than 44,000 Boehringer Ingelheim employees worldwide.
- Our drug discovery focuses on six major therapeutic areas: Respiratory diseases, Cardiometabolic diseases, Oncology, Neurological diseases, Immunology, Infectious diseases.
- In 2011, Boehringer Ingelheim posted net sales of 13,2 billion euro while investing almost 24 percent of net sales in our largest business segment Prescription Medicines on research and development.
